Amarin Corp Plc (AMRN)

[ziploc_1]

Retinadoc...QUOTE.."She noted that more mechanistic and clinical data are needed to hone in on which patients will derive the most benefit, such as those with elevated high-sensitivity C-reactive protein or highest change in EPA levels."

Consequent to judge Du's decision, which paved the way for infringement of the Vascepa CVD indication by generics, Amarin does not now and will never have sufficient assets to do what Dr. Taub is calling for...The infringing generics have no interest in doing these studies....The only way for these studies to be implemented is for Amarin to be sold to a BP.